FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center

Bengoa S. Y. , Ataseven E., Kizmazoglu D., Yenigurbuz F. , Erdem M., Oren H.

TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.46-51, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.4274/tjh.2015.0411
  • Title of Journal : TURKISH JOURNAL OF HEMATOLOGY
  • Page Numbers: pp.46-51

Abstract

Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.